<DOC>
	<DOCNO>NCT00002114</DOCNO>
	<brief_summary>To compare efficacy safety orally administer Procysteine placebo HIV-infected patient receive 1 following : ( 1 ) zidovudine ( AZT ) alone ; ( 2 ) didanosine ( ddI ) alone ; ( 3 ) AZT plus ddI ; ( 4 ) AZT plus zalcitabine ( ddC ) .</brief_summary>
	<brief_title>A Double-Blind , Randomized Parallel Group Study Comparing Procysteine Placebo HIV-Infected Patients Who Are Taking Antiretroviral Nucleosides</brief_title>
	<detailed_description>All patient must receive treatment antiretroviral nucleoside addition study treatment . Patients randomize equally 1 3 outpatient dosage group . Group 1 receive placebo ; Group 2 receives low dose Procysteine ; Group 3 receive high dose Procysteine . Patients receive study treatment 6 month ( total duration patient participation 30 week ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Antiretroviral nucleoside ( AZT alone , ddI alone , AZT plus ddI , AZT plus ddC ) . Regimen may alter Week 16 . Allowed : Appropriate topical treatment local radiotherapy KS . Treatment prophylaxis opportunistic infection , include pentamidine , cotrimoxazole , acyclovir , fluconazole , etc. , discretion investigator . Patients must : Documented serologic evidence confirm HIV infection . Ability participate outpatient study least 26 week . Either : ( ) diagnosis AIDS AIDSRelated Complex ( ARC ) CD4 count 50 300 cells/mm3 , ( b ) CD4 count 50 200 cells/mm3 symptom AIDS ( asymptomatic ) . ( Note : Patients whose AIDSdefining condition Kaposi 's sarcoma alone must CD4 count 50 200 cells/mm3 . ) Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Evidence organ involvement CMV and/or positive blood culture Mycobacterium avium . Life expectancy le 26 week . Malignancy advance Kaposi 's sarcoma ( KS ) advance unstable skin lesion , know suspected visceral disease require systemic cytotoxic , myelosuppressive chemotherapy . Stage 2 great AIDSdementia complex ( ADC ) , define ability perform basic activity selfcare inability work maintain demand aspect daily life result acquire decrease cognitive CNSrelated motor function characteristic ADC . Psychological emotional problem prevent adequate compliance study therapy . Concurrent Medication : Excluded : Daily Vitamin C dosage great 1,000 mg daily Vitamin E dosage great 100 unit . Nacetylcysteine , cysteine , glutathione . Any investigational drug . Systemic chemotherapy . Patients follow prior condition exclude : History organ involvement cytomegalovirus ( CMV ) and/or positive blood culture Mycobacterium avium . Intractable diarrhea , define great 4 bowel movement per day least 2 week . History seizures control appropriate anticonvulsant medication within previous 6 month . Prior Medication : Excluded : Any investigational agent biological response modifier ( include interferon corticosteroid ) within 1 month study entry . Use erythropoietin ( EPO ) , GCSF , GMCSF within 28 day randomization . Risk Behavior : Excluded : Active alcohol drug abuse . Required : Antiretroviral nucleoside ( AZT alone , ddI alone , AZT plus ddI , AZT plus ddC ) least 3 month prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1994</verification_date>
</DOC>